Meeting
2018 Gastrointestinal Cancers Symposium
Phase II study of FOLFIRI + ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin / fluoropyrimidine (RAINCLOUD).
Authors
Naotoshi Sugimoto
Osaka International Cancer Institute, Osaka, Japan
Naotoshi Sugimoto , Chu Matsuda , Taishi Hata , Taroh Satoh , Masakazu Ikenaga , Tsunekazu Mizushima , Kohei Murata , Masayuki Ohue , Yuichiro Doki , Masaki Mori
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000028677
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr TPS882)
DOI
10.1200/JCO.2018.36.4_suppl.TPS882
Abstract #
TPS882
Poster Bd #
Q10
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922.
First Author: Michael J. Overman
First Author: Axel Grothey
Poster
2012 Gastrointestinal Cancers Symposium
Phase II study alternating mFOLFOX 6 and FOLFIRI (FIREFOX) plus bevacizumab (bev) regimen in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0801).
First Author: Yutaka Ogata
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical development and evaluation of plasma angiogenesis factors from phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin/fluoropyrimidine (RAINCLOUD): RAINCLOUD-TR.
First Author: Tsuyoshi Hata